News

FDA Accepts Priority Review Request for Tyvaso DPI

The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics’ application for a priority review of Tyvaso DPI, an experimental dry powder inhaled formulation of treprostinil, to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). …

Microgel-coated Cells Reverse Established PF in Mice

Scientists found that mesenchymal stromal cells (MSCs) — cells that have similar properties to stem cells — individually coated with a soft microgel were able to reverse established lung tissue scarring in a mouse model of pulmonary fibrosis.  Their findings were reported in…

Esbriet Slows IPF Progression Regardless of Self-reactive Antibodies

Esbriet (pirfenidone) appears to slow the progression of idiopathic pulmonary fibrosis (IPF) regardless of the presence of autoantibodies, which might mean the therapy can work even when IPF is linked to an autoimmune disease, a study suggests. The study, “Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according…

Cedars-Sinai, Rubedo Partner to Develop Targeted IPF Treatments

Rubedo Life Sciences announced that it has partnered with Cedars-Sinai Medical Center, also in California, to advance its idiopathic pulmonary fibrosis (IPF) program and conduct collaborative research. The biopharmaceutical’s IPF program focuses on developing senolytics, or small molecules that target harmful senescent cells. These cells increase inflammation, fibrosis…